Clinician Perspective on the Benefits of Niacin Therapy for the Treatment of Dyslipidemia and Strategies to Improve Long-Term Adherence to Therapy
The following Expert Roundtable Discussion was held on November 23, 2011. Dr. Peter H. Jones from the Baylor College of Medicine moderated the topic “Clinician Perspective on the Benefits of Niacin Therapy for the Treatment of Dyslipidemia and Strategies to Improve Long-Term Adherence to Therapy” with Dr. Bradley Bale of the Grace Clinic and Texas Tech Health Science Center and Amy Doneen from the Heart Attack and Stroke Prevention Center, Spokane, WA and Texas Tech Health Science School of Nursing.
The discussion focused primarily on: (1) when and how to use niacin in clinical practice; (2) how to manage the expected flushing reaction that may interfere with compliance and adherence; (3) educating the patient on niacin’s benefit and benign effect of flushing; and (4) a current trial that aims to answer the broader questions about the use of niacin above and beyond what was shown in the AIM-HIGH trial. (Med Roundtable Cardiovasc Ed. 2011;2(4):249–255) ©2011 FoxP2 Media, LLC
TRIAL DISCUSSED: ASTEROID, AIM-HIGH, ARBITER 6, INTERHEART, Framingham Heart Study, Women’s Health Study, INTERSTROKE, HATS, HPS2-THRIVE, Helsinki Heart Study, VA-HIT
COMPOUNDS DISCUSSED: rosuvastatin, niacin, ezetimibe, laropiprant
Click here to download and read the full Expert Roundtable Discussion.